Clearbridge Investments LLC Cuts Stake in Medpace Holdings, Inc. $MEDP

Posted by Brenda Bartman on Jun 8th, 2026

Clearbridge Investments LLC lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 20.0% in the fourth quarter, Holdings Channel reports. The firm owned 205,182 shares of the company’s stock after selling 51,382 shares during the period. Clearbridge Investments LLC’s holdings in Medpace were worth $115,241,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Optiver Holding B.V. purchased a new stake in shares of Medpace during the third quarter worth about $27,000. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace during the fourth quarter worth about $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace during the fourth quarter worth about $30,000. Finally, Quarry LP purchased a new stake in shares of Medpace during the third quarter worth about $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $454.25 on Monday. Medpace Holdings, Inc. has a 12-month low of $294.07 and a 12-month high of $628.92. The stock has a market cap of $12.97 billion, a PE ratio of 28.55, a P/E/G ratio of 2.30 and a beta of 1.18. The company has a 50-day moving average of $456.73 and a 200 day moving average of $508.39.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue was up 26.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on MEDP shares. Leerink Partners cut their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Truist Financial dropped their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada dropped their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $467.08.

Read Our Latest Analysis on Medpace

Medpace News Summary

Here are the key news stories impacting Medpace this week:

Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Insider Activity

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 20.50% of the company’s stock.

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.